Signios Biosciences Unveils Rebrand and Expands Vision as a Leading Multiomics and AI Bioinformatics Innovator in Precision Medicine
In a bold step forward reflecting its evolution and expanded capabilities, Signios Biosciences (formerly the U.S.-based research division of MedGenome Inc.) has officially rebranded, ushering in a new era of scientific collaboration, cutting-edge discovery, and transformative impact in precision medicine. Announced today, the rebranding signals not only a name change but a strategic repositioning of the company as a standalone biotechnology leader headquartered in the United States. It positions Signios Biosciences—now Signios Bio—as a dedicated, science-first partner for the global biomedical research community, with a sharpened focus on decoding complex disease biology using advanced multiomics and AI-powered bioinformatics.
The transformation from a research division into an independent brand with a global vision represents a milestone moment for Signios Bio. The company emerges from its origins with deep scientific roots, ready to build on its legacy with a bold, integrated approach to biomedical discovery. Through its expanded offerings and strategic direction, Signios Bio aims to redefine how the scientific community interprets biological complexity and translates it into actionable clinical insights.
A New Identity with a Mission-Driven Focus
The rebranding of Signios Bio is not merely cosmetic—it is emblematic of the company’s evolution into a full-spectrum biotechnology partner. With its tagline “The Cure is in the Code,” Signios Bio encapsulates a powerful philosophy that emphasizes the importance of extracting insights hidden deep within the layers of biological data. By focusing on signals—rather than noise—within the biological code, Signios Bio seeks to accelerate breakthroughs in diagnostics, therapeutic development, and personalized medicine.
“Our focus is on partnering with researchers and organizations to decode biology in ways that are inclusive, rigorous, and globally relevant,” said Felix Olale, MD, PhD, CEO and President of Signios Bio. “In an era where the challenge is no longer just generating biological data but making sense of it, our goal is to reveal the biological signals that matter most—those that drive disease progression, guide treatment decisions, and ultimately, save lives.”
Dr. Olale’s statement reflects a vision rooted in scientific excellence but powered by technology and translational potential. With a strong foundation in multiomics—including genomics, transcriptomics, proteomics, epigenomics, metabolomics, microbiomics, and spatial biology—Signios Bio offers an end-to-end, integrated suite of services powered by its proprietary AI-driven bioinformatics platform. This convergence of wet lab execution and computational power enables the company to support everything from early discovery to late-stage clinical studies.
Multiomics, Bioinformatics, and the Next Frontier in Precision Medicine
What sets Signios Bio apart in a competitive and rapidly evolving biotech landscape is its commitment to comprehensive multiomic analysis paired with powerful informatics tools. While the generation of omics data is increasingly common, the ability to derive insights across layers of biology—connecting genomics to proteomics to metabolomics and beyond—remains a major challenge. Signios Bio’s integrated platform enables precisely that.
“Our scientific model is not built around isolated data types or siloed discoveries,” said Harsha Gowda, PhD, Head of Science and Laboratory Operations. “We believe that by bringing together multiomic data at scale, supported by cutting-edge AI analytics, we can offer our partners a new level of biological insight—one that is contextual, functional, and clinically relevant.”
Through this integrated framework, Signios Bio supports biopharma companies, biotech startups, and academic institutions in unraveling the complexity of diseases such as cancer, neurodegeneration, autoimmune disorders, and rare genetic syndromes. By identifying biomarkers, elucidating disease mechanisms, and enabling precise stratification of patient populations, the company provides critical tools to inform the development of targeted therapeutics and diagnostics.
Expanding the Scientific Arsenal: Spatial Proteomics and Antibody Discovery
As part of its rebranding and expansion strategy, Signios Bio is also enhancing its capabilities in spatial proteomics and antibody discovery—two fast-emerging areas that are reshaping the future of biomedical research. Spatial proteomics, which enables the high-resolution mapping of protein expression within tissue microenvironments, offers profound insights into disease biology at the cellular and subcellular level. This is particularly relevant in fields like oncology and immunology, where understanding cellular context is critical to developing effective therapies.
Similarly, the company’s foray into antibody discovery reflects a commitment to pushing the boundaries of systems biology. With a foundation in high-throughput screening and AI-augmented antibody engineering, Signios Bio aims to support therapeutic programs from early discovery through preclinical development.
“These new capabilities allow us to go beyond static data and into dynamic biological processes,” noted Marco Corbo, PhD, Head of Bioinformatics. “We’re not just generating snapshots—we’re building functional, spatial, and temporal models of disease that can inform intervention points and drug development strategies.”
A Scientific Partner, Not Just a Service Provider
Beyond its technological sophistication, what truly differentiates Signios Bio is its approach to collaboration. The company positions itself as a scientific partner rather than a vendor—working shoulder to shoulder with clients to co-design studies, interpret results, and chart a path to translational success.
Whether it’s a large pharmaceutical company seeking biomarker-driven patient stratification, a biotech startup exploring novel targets, or an academic lab designing complex multiomic studies, Signios Bio provides a bespoke engagement model tailored to each partner’s unique goals.
“Partnership is at the heart of everything we do,” said Jennifer Rose, MS, Chief Commercial Officer. “We recognize that science doesn’t move forward in isolation—it thrives through collaboration, shared insights, and a commitment to mutual success.”
Promoting Global Representation and Real-World Impact
In addition to scientific innovation, Signios Bio is dedicated to advancing health equity through inclusive research practices. The company is uniquely positioned to leverage global real-world data and support clinical studies that are representative of diverse populations—an increasingly recognized necessity in the field of precision medicine.
Through international collaborations and partnerships with healthcare institutions worldwide, Signios Bio works to close the gap in underrepresented populations in clinical research. This commitment ensures that the next generation of diagnostics and therapeutics is both effective and equitable—delivering solutions that work for everyone, everywhere.
